Market research

RPHM Reneo Pharmaceuticals Inc

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 61M
P/E ratio: Not available
Analyst target: 2.25
Dividend yield: Not available
Beta: 0.22

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US75974E1038
Market cap: 61M
P/E ratio: Not available
Analyst target: 2.25
Dividend yield: Not available
Beta: 0.22

About

About Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about RPHM.

RPHM Reneo Pharmaceuticals Inc

Price & volume

Company facts

About Reneo Pharmaceuticals Inc

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet